Tagged with

Brazil Armando Correa Lopes Jr, managing director of Siemens Healthineers Brazil, provides insights into the main trends and challenges at the core of Brazil’s healthcare discussion and documents the contribution of Siemens Healthineers in shaping a more cost-efficient, value-based, and data-oriented Brazilian model of healthcare. Leveraging your long-standing experience of Brazil’s…

Poland Agnieszka Grzybowska-Zalewska, general manager of Sanofi Genzyme Poland, reflects on the company’s stable growth over the last few years and the market access challenges they have encountered along the way. Moreover, she highlights the importance of achieving reimbursement for three key products for Multiple Sclerosis and Oncology as well as…

Serbia Ljubiša Mitof-Višurski, general manager for AbbVie Adria, discusses the main challenges, opportunities and synergies the Adria region has to offer. He underlines the key healthcare initiatives AbbVie engages with in the region, as well as the crucial role the company plays in bringing innovative solutions to patients. Can you provide…

Lithuania Raimundas Voishka, country manager Lithuania and Belarus at Pfizer, highlights the increasing openness of the Baltic region towards innovation and stresses the commitment of Pfizer to bringing innovative as well as added-value medicines to the region. You have more than 20 years of experience in the Lithuanian pharmaceutical industry. What…

Serbia Goran Djuric, the founder of EuroCons Group, shares an overview of the rationale and business scope of the company’s activities while underlining the importance of bringing innovative solutions to the market. Further, he discusses the particular initiatives the company is involved in, as well as sharing his advice for entrepreneurs…

Serbia Milos Davidovic, Mylan’s country manager responsible for Serbia, Slovenia, Macedonia, and Montenegro, reveals the made-to-measure market approach that he has been implementing in the region for the past six years while highlighting the crucial role of employing a highly educated, expert workforce. What potential did Mylan see in Serbia, and…

Canada David Main, CEO and president of Aquinox Pharmaceuticals Inc., introduces the company he founded in 2006, which now is in the late stages of development of a drug targeting the SHIP1 enzyme, with a focus on treating interstitial cystitis/bladder pain syndrome. Other applications may include blood cancers and chronic prostatitis/chronic…

Serbia Founder and general director of INNventa, Goran Orlic, discusses the rationale behind establishing his own company that continues to double revenues year on year. He highlights the company’s fundamental role in providing innovative solutions to Serbian patients, pharmacists and doctors. Finally, he discusses investment opportunities in the Balkans, underlining the…

Poland Dr. Wolfgang Wagner, regional director of Wörwag EU and CEE, highlights the ongoing process of the company to integrate itself within each respective healthcare community so patients can receive better market access to their biofactor therapies. Furthermore, he discusses the need to highlight the pharmacoeconomic impact of their products to…

Brazil Tatiane Galindo, executive director of Ortosintese, Brazil’s and Latin America’s leading implant company, provides insights into Ortosintese’s historical commitment to the highest quality standards and her ambitions to further bolstering the development of innovative projects as well as the company’s international footprint, while Ortosintese’s implants are already available in over…

Brazil Fernando Itzaina, president and CEO of FQM Group, originally Farmoquímica, provides inspiring insights into the threefold development vision favored by this rapidly growing pharmaceutical company, his commitment to continue exploring both organic and inorganic growth options in order to better service Brazilian patients and physicians, as well as FQM’s enduring…

Canda Richard Lajoie shares his main priorities for his tenure as new president of Valeant’s Canadian operations: portfolio rejuvenation through launches of innovative molecules addressing the unmet needs of Canadian patients, growing the company’s manufacturing capacity in the country and fostering the Valeant culture. What does Canada represent for Valeant today?…